March 27, 2024 01:24 PM EDT
Pharma

On­copep­tides joins up with Vec­tor to com­mer­cial­ize blood can­cer drug Pepax­to in the Mid­dle East, North Africa

Katherine Lewin

News Reporter

About a month af­ter On­copep­tides lost its ap­peal with the FDA to con­tin­ue the ap­proval for Pepax­to in mul­ti­ple myelo­ma pa­tients, the com­pa­ny an­nounced it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times